Literature DB >> 12619820

Control of pyrimidine formation in Pseudomonas putida ATCC 17536.

Manuel F Santiago1, Thomas P West.   

Abstract

The regulation of de novo pyrimidine biosynthesis in Pseudomonas putida ATCC 17536 by pyrimidines was explored. The pathway enzyme activities were higher in glucose-grown cells than in succinate-grown cells, indicating catabolite repression by succinate. In P. putida cells grown on succinate as a carbon source, only aspartate transcarbamoylase activity was greatly diminished by uracil supplementation. When glucose was the carbon source, orotic acid supplementation significantly decreased orotate phosphoribosyltransferase and orotidine 5'-monophosphate (OMP) decarboxylase activities. Uracil auxotrophs, deficient for dihydroorotase activity or with reduced phosphoribosyltransferase activity, were isolated. After pyrimidine limitation of both auxotrophs, the greatest derepression of enzyme activity was observed for OMP decarboxylase independent of carbon source. Orotic acid induced both phosphoribosyltransferase and decarboxylase activities in glucose-grown cells of the dihydroorotase-deficient strain. Regulation at the transcriptional level of de novo pyrimidine biosynthetic enzyme synthesis in P. putida ATCC 17536 was observed, which contrasts with previous observations.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12619820     DOI: 10.1139/w02-110

Source DB:  PubMed          Journal:  Can J Microbiol        ISSN: 0008-4166            Impact factor:   2.419


  2 in total

1.  Accumulation of Pyrimidine Intermediate Orotate Decreases Virulence Factor Production in Pseudomonas aeruginosa.

Authors:  Abdurahman Niazy; Lee E Hughes
Journal:  Curr Microbiol       Date:  2015-04-28       Impact factor: 2.188

2.  Transposon insertion libraries for the characterization of mutants from the kiwifruit pathogen Pseudomonas syringae pv. actinidiae.

Authors:  Carl H Mesarich; Jonathan Rees-George; Paul P Gardner; Fatemeh Ashari Ghomi; Monica L Gerth; Mark T Andersen; Erik H A Rikkerink; Peter C Fineran; Matthew D Templeton
Journal:  PLoS One       Date:  2017-03-01       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.